In conclusion, although the existing data suggest a correlation between CSF and serum CHI3L1 levels and MS progression, especially in progressive forms, more studies are necessary to fully comprehend the relationship between this biomarker and disease severity, activity, and progression. The gene discussed is CHI3L1; the disease is myeloid sarcoma.